Portal de Periódicos da CAPES

Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies

2010; Springer Science+Business Media; Volume: 13; Issue: 2 Linguagem: Inglês

10.1007/s10120-010-0555-2

1436-3305

Shinichi Hasegawa, Takaki Yoshikawa,

Gastrointestinal Tumor Research and Treatment

The incidence of adenocarcinoma of the esophagogastric junction (AEG) is dramatically increasing in Western countries, while it is not increasing in Eastern countries. Siewert type I tumors are observed less frequently in Eastern countries in comparison to Western countries. On the other hand, other clinicopathological features of AEG, including age, male-to-female ratio, pathological grade, tumor progression, and prognosis, are similar in Western and Eastern countries. Two surgical phase III trials have indicated that AEG type I should be treated surgically as esophageal cancer, while types II and III should be regarded as true gastric cancer. No phase III trials have demonstrated a significant interaction comparing hazard ratios for death between AEG and true gastric cancer in the subset analyses with regard to chemotherapy.